Finanzen von Acumen Pharmaceuticals Inc (ABOS)ABOSAcumen Pharmaceuticals Inc

Evaluating the bottom line, Acumen Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -120.50%, provide a clear picture of how effectively ABOS converts its operational activities into shareholder value.

In the context of the broader market, ABOS competes directly with industry leaders such as MENS and TLSA. With a market capitalization of $126.19M, it holds a significant position in the sector. When comparing efficiency, ABOS's gross margin of N/A stands against MENS's N/A and TLSA's N/A. Such benchmarking helps identify whether Acumen Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Acumen Pharmaceuticals has reported consistent net losses, with Q2 2026 showing a net loss of $32.72 million, and a negative EPS of $0.45, reflecting ongoing financial struggles.